Non-regulatory Press releases

Malmö, 05 March 2026 PILA PHARMA AB (publ) (FN STO: PILA) ("PILA" or the "Company"), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition, today shares its participation at the BIO-Europe Spring conference in Lisbon, Portugal from 23-25 March. The company's CEO Gustav H. Gram will represent the Company and discuss its proprietary oral small molecule…

Malmö, 05 March 2026 PILA PHARMA AB (publ) (FN STO: PILA) ("PILA" or "the Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, informs of the conversion of TO2 warrants to shares, and the disclosure of participation from management members. Malmö, 05 March 2026 The subscription period for exercise of the warrants of series TO2 took…

Malmö, 17 February 2026 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announced the outcome of exercise in warrants of series TO2. The subscription period for exercise of the warrants of series TO2 took place during the period from and including 5 February 2026, up to and including…

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE…

Malmö, 11 February 2026 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A.  CEO Gustav H. Gram gave an online interview and Q&A at 14:00 CET on 10 February 2026, in connection with the publication of the company's H2 / Year-end report. The event was…